These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 1846943

  • 1. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
    Turski L, Bressler K, Rettig KJ, Löschmann PA, Wachtel H.
    Nature; 1991 Jan 31; 349(6308):414-8. PubMed ID: 1846943
    [Abstract] [Full Text] [Related]

  • 2. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon.
    Sawada H, Shimohama S, Tamura Y, Kawamura T, Akaike A, Kimura J.
    J Neurosci Res; 1996 Jan 01; 43(1):55-62. PubMed ID: 8838574
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the time courses of selective gene expression and dopaminergic depletion induced by MPP+ in MN9D cells.
    Wang J, Duhart HM, Xu Z, Patterson TA, Newport GD, Ali SF.
    Neurochem Int; 2008 May 01; 52(6):1037-43. PubMed ID: 18069091
    [Abstract] [Full Text] [Related]

  • 4. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T.
    Synapse; 1997 Aug 01; 26(4):381-91. PubMed ID: 9215597
    [Abstract] [Full Text] [Related]

  • 5. A cell-permeable peptide inhibitor TAT-JBD reduces the MPP+-induced caspase-9 activation but does not prevent the dopaminergic degeneration in substantia nigra of rats.
    Pain S, Barrier L, Deguil J, Milin S, Piriou A, Fauconneau B, Page G.
    Toxicology; 2008 Jan 14; 243(1-2):124-37. PubMed ID: 18037221
    [Abstract] [Full Text] [Related]

  • 6. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats.
    Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ.
    J Neurochem; 1992 May 14; 58(5):1979-982. PubMed ID: 1560247
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D, Samantaray S, Mohanakumar KP.
    Synapse; 2003 Oct 14; 50(1):7-13. PubMed ID: 12872288
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
    Chan P, Langston JW, Di Monte DA.
    J Pharmacol Exp Ther; 1993 Dec 14; 267(3):1515-20. PubMed ID: 8263813
    [Abstract] [Full Text] [Related]

  • 12. MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress.
    Fallon J, Matthews RT, Hyman BT, Beal MF.
    Exp Neurol; 1997 Mar 14; 144(1):193-8. PubMed ID: 9126170
    [Abstract] [Full Text] [Related]

  • 13. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss.
    Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT.
    Neurobiol Aging; 1993 Mar 14; 14(4):295-301. PubMed ID: 8103573
    [Abstract] [Full Text] [Related]

  • 14. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.
    Chan P, Di Monte DA, Langston JW, Janson AM.
    J Pharmacol Exp Ther; 1997 Jan 14; 280(1):439-46. PubMed ID: 8996226
    [Abstract] [Full Text] [Related]

  • 15. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
    Van Kampen JM, McGeer EG, Stoessl AJ.
    Synapse; 2000 Sep 01; 37(3):171-8. PubMed ID: 10881039
    [Abstract] [Full Text] [Related]

  • 16. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    Fornai F, Alessandrì MG, Torracca MT, Bassi L, Corsini GU.
    J Pharmacol Exp Ther; 1997 Oct 01; 283(1):100-7. PubMed ID: 9336313
    [Abstract] [Full Text] [Related]

  • 17. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A, Fascetti F, Corsini GU, Piccardi MP.
    Exp Neurol; 1994 May 01; 127(1):54-61. PubMed ID: 8200437
    [Abstract] [Full Text] [Related]

  • 18. Excitatory amino acid-induced degeneration of dendrites of catecholamine neurons in rat substantia nigra.
    Johnson SM, Bywood PT.
    Exp Neurol; 1998 Jun 01; 151(2):229-36. PubMed ID: 9628758
    [Abstract] [Full Text] [Related]

  • 19. Modification by apomorphine of the circling behaviour in the rat due to unilateral intranigral injection of 1-methyl-4-phenylpyridine (MPP+).
    Lange KW.
    J Toxicol Clin Exp; 1989 Jun 01; 9(1):21-5. PubMed ID: 2787400
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.